Gujarat Themis Biosyn shares rose up to 6% intraday after shareholders approved a QIP and NCD fundraise, alongside strong Q1 results.

The fundraising approval came through a postal ballot process. Shareholders voted on three special resolutions between 24 July and 22 August, and all three passed with near-unanimous support, ranging from 99.97% to 99.99% in favour.

This gives the company a formal go-ahead to raise up to ₹1,000 crore through a qualified institutional placement and up to ₹1,500 crore through non-convertible debentures.

Notably, the promoter group sat out the voting on the QIP resolution. For the QIP itself, the board has already set a floor price of ₹372.57 per share, with room for a discount of up to 5%.

The trading window for designated persons within the company has been closed since 25 August and will stay shut until 48 hours after the final issue price is set.

Alongside the fundraising update, the company’s Q1 FY27 numbers gave investors another reason to buy.

Operational income rose to ₹43.79 crore from ₹35.87 crore a year earlier, while net profit climbed 22% to ₹11.07 crore.

Margins improved too, with EBITDA up sharply and the EBITDA margin expanding to 47.5% from 38.8% in the same quarter last year.

The company has also been working on two overseas deals in recent months, an acquisition of Japan’s MicroBiopharm and a separate agreement to buy a set of Sanofi brands, both of which the fresh capital is expected to help fund.

Management has described these deals as central to its plan to grow into a global player in fermentation-based pharmaceutical manufacturing.

As of 14:09 pm on 26 August, Gujarat Themis Biosyn shares were trading at ₹420.10 on the NSE, up 3.79% for the day, after opening at ₹401.75 against a previous close of ₹404.70.

Discover the next big investment!

Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings.

Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!